Hikma launches generic posaconazole oral suspension

Hikma is introducing posaconazole oral suspension in a 40 mg/ml dose, which will be the first generic of this medication on the market. 

Posaconazole oral suspension is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy in adult and pediatric patients aged 13 years]and older. Posaconazole oral suspension also is indicated for the treatment of oropharyngeal candidiasis, including OPC refractory to itraconazole and/or fluconazole in adult and pediatric patients aged 13 years and older.

[Read more: Hikma acquires Custopharm]

Posaconazole oral suspension had a market value of approximately $16 million in the 12 months ending January 2023, according to IQVIA.

[Read more: Hikma launches generic Vascepa]